肺癌中表皮生长因子受体基因的临床和生物学特点。
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers.
非小细胞肺癌病人的表皮生长因子受体基因突变的临床病理意义。
Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non-Small Cell Lung Cancer.
背景：Flt3基因是近年来发现的早期造血生长因子受体基因。
BACKGROUND: Fms-like tyrosine kinase-3 (FLT3) gene is one of the receptors for growth factors in early hematogenesis.
“从不吸烟的患者对一类叫表皮生长因子受体抑制剂的药物反应更好，因为这类患者有表皮生长因子受体基因突变的可能性更大一些。”鲁丁说。
"Patients who never smoked respond better to a certain class of drugs called EGFR inhibitors, because lung cancer in these patients more often contain mutations in the EGFR gene," Rudin says.
在侵袭性脑胶质瘤中，表皮生长因子受体基因拷贝数更高，而且一半的侵袭性脑胶质瘤伴有一个GEFR突变。这个突变增加了肿瘤的生长，伴随一个糟糕的预后效果。
In aggressive gliomas, extra copies of the EGFR gene are produced, and half of such tumors also carry an EGFR mutation, which ramps up tumor growth and portends a poor prognosis.
表皮生长因子受体通常促进细胞的生长发育，一旦发生基因变异，会使细胞不受控制地生长。细胞不受控制地生长，这正是癌症的特征。
EGFR normally promotes cell growth and development, and when mutated, allows the uncontrolled growth of cells that is the hallmark of cancer.
十多年前就取得了重大进展，一个加州的生物科技公司Genentech(中文名：基因泰克)发行了一种药物，这种药物攻击蛋白质HER2(中文名：人表皮生长因子受体- 2)含量过多的乳腺癌细胞。
A breakthrough came more than a decade ago when Genentech, a Californian biotech firm, launched a drug that attacks breast-cancer cells with too much of a certain protein, HER2.
转录最高的基因与功能相关，如细胞粘附，基质蛋白，生长因子，受体和蛋白酶。
The most highly transcribed genes relate to functional groupings such as cell adhesion, matrix proteins, growth factors and receptors, and proteases.
目的探讨胰腺癌细胞（PC-3）胰岛素样生长因子-1受体（IGF- 1R）基因的定量表达，及其与细胞凋亡、成瘤性的关系。
Objective To explore Insulin like growth factor 1 receptor(IGF 1R)gene quantitative expression in human pancreatic cancer cells(PC 3) and the relationship of IGF 1R with apoptosis?tumorigenicity.
这是FDA批准的首个能够检测非小细胞肺癌患者表皮生长因子受体(EGFR)基因突变的、以血液为基础的基因检测试剂盒。
This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.
表皮生长因子受体(EGFR)通路下游基因的激活突变可以引起结直肠癌患者抗egfr耐药。
Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR) pathway may cause anti-EGFR resistance in patients with colorectal cancers.
目的研究胰岛素样生长因子i受体(IGFIR)基因表达对脐血t淋巴细胞功能的影响及其临床意义。
Objective to study the role of insulin like growth factor type I receptors (IGF IR) in the modulation of cord blood t lymphocyte functions and its clinical significance.
目的：探讨表皮生长因子受体(EGFR)基因酪氨酸激酶域体细胞在肺腺癌患者中突变的相关因素。
Objective: to study Somatic mutation of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR gene) in lung adenocarcinoma patients.
本文对垂体腺瘤中基因突变、转录因子、细胞表达受体、生长因子的作用及关系作一述评。
This paper reviews the roles of gene mutations, transforming factors, expression of receptors on cells and growth factors in the etiology of pituitary adenomas.
目的克隆人表皮生长因子受体（HER2）基因，建立共表达HER2基因和雌激素受体（ER）基因的MCF-7细胞模型。
Objective To clone human epidermal growth factor receptor (HER2) gene and establish a MCF-7 cell line with stable co-expression of HER2 and estrogen receptor (ER).
目的探讨中国人非小细胞肺癌表皮生长因子受体(EGFR)第18、19、21外显子基因突变状态。
Objective to study the mutation patterns of epithelial growth factor receptor (EGFR) exon 18, 19 and 21 in Chinese non-small-cell lung cancers (NSCLC).
目的观察表皮生长因子受体（EGFR）在口腔复发性阿弗他溃疡（RAU） 组织中蛋白和基因表达变化。
Objective To explore the expression change of protein and mRNA of EGFR(epidermal growth factor receptor)in RAU(recurrent aphthous ulcer).
目前认为垂体腺瘤的发生与基因突变、生长因子、细胞受体、转录因子和细胞信号通路等有关。
The pathogenesis of pituitary adenomas is considered to be related with gene mutation, growth factors, cell receptors, transcription factors, and cellular signaling pathways.
目的探讨外周血表皮生长因子受体(EGFR)基因突变在非小细胞肺癌(NSCLC)吉非替尼治疗适宜患者筛选中的价值。
Objective to evaluate the clinical significance of epidermal growth factor receptor EGFR mutations in the treatment of non-small cell lung cancer NSCLC.
目的探讨外周血表皮生长因子受体(EGFR)基因突变在非小细胞肺癌(NSCLC)吉非替尼治疗适宜患者筛选中的价值。
Objective to evaluate the clinical significance of epidermal growth factor receptor EGFR mutations in the treatment of non-small cell lung cancer NSCLC.
应用推荐